AdvaMed Reworks ASR Language In Hopes Of Influencing New FDA Guidance
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed currently is gathering information, including legal opinions, on how current analyte specific reagent regulations could be altered
You may also be interested in...
Lab Stakeholders Still Oppose FDA’s Multivariate Assay Policy
Laboratories are urging FDA to once again rework, if not abandon, its proposal to actively regulate certain lab-developed tests, while diagnostics companies are split on the issue
Lab Stakeholders Still Oppose FDA’s Multivariate Assay Policy
Laboratories are urging FDA to once again rework, if not abandon, its proposal to actively regulate certain lab-developed tests, while diagnostics companies are split on the issue
Ambiguity On Diagnostic Regs Has Led To Tough Choices, Says CEO
In the current regulatory environment for genetic tests, a manufacturer's best business plan may dictate an opposite path to market than its concerns about patient safety, says Tm Bioscience CEO Greg Hines